AllDocs -> cancers

1 Testimony of the Pancreatic Cancer Action Network, Inc. (PanCAN) 2221 Rosecrans Avenue. Suite 131 El Segundo, CA 90245 Submitted to the Labor, Health and Human Services and Education Subcommittee of the House Appropriations Committee By Ms. Julie Fleshman President & CEO PanCAN on April 15, 2005 Dear Chairman Regula and Colleagues: Every 17 minutes someone in the United States dies of pancreatic cancer . This year, over 32,180 Americans will be diagnosed with pancreatic cancer and 31,800 will die from this disease. The 99% mortality rate for pancreatic cancer remains the highest of all cancers, and the average life expectancy is three to six moths after diagnosis with metastatic disease. There are no early detection programs, effective treatments or cures for pancreatic cancer . At a time when so much progress is being made in medical ...

F ungi native to East Africa could be used as a new tool in the fight against malaria, recent studies suggest. According to BBC News website, an international team of scientists from the Netherlands, Tanzania and the UK say their technique could significantly reduce malaria cases. Their research has been presented at the Fourth pan-African Malaria Conference in Yaounde, Cameroon. When fungi infect cer- tain insects, including malaria-carrying mosqui- toes, they grow and quick- ly kill the animal. New studies show that a specific type of fungus native to East Africa can infect mosquitoes and reduce their lifespan by two-thirds - to just seven days. Professor Willem Takken from Wageningn University in the Netherlands said the fun- gus also stops live mosqui- toes from transmitting ...

JOP. J Pancreas (Online) 2005; 6(6):552-561. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 6, No. 6 – November 2005. [ISSN 1590-8577] 552 REVIEW Value of Laparoscopy in the Staging of Pancreatic Cancer Diego Camacho, Dan Reichenbach, Georg D Duerr, Tammy L Venema, John F Sweeney, William E Fisher The Elkins Pancreas Center, Michael E DeBakey Department of Surgery, Baylor College of Medicine. Houston, Texas, USA Summary Pancreatic cancer is a devastating disease that swiftly robs patients of both quality and quantity of life. It is the fourth leading cause of cancer death in the United States. In 2003, there were 31,860 reported new cases with 31,270 deaths occurring due to lack of effective therapy. Eighty percent of patients present with either advanced local or metastatic disease. Dynamic contrast- enhanced computed tomography ...

Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomics Approach Mads Grønborg 1,2 , Troels Zakarias Kristiansen 1,2 , Akiko Iwahori 1 , Rubens Chang 3 , Raghunath Reddy 1 , Norihiro Sato 3 , Henrik Molina 1,2 , Ole Nørregaard Jensen 2 , Ralph H. Hruban 3,4 , Michael G. Goggins 3 , Anirban Maitra 1,3,4 and Akhilesh Pandey 1,4* 1 McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD 21205, USA 2 Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, Odense M, Denmark Department of 3 ...

Contact: Paul Hopper Rob Whetstone/Rosemary Moothart Managing Director Investor Relations Australian Cancer Technology PondelWilkinson Inc. Phone: +61 2 9252 6899 Phone: (310) 279-5980 (U.S.) Mob: +61 407 118 366 Email: paulhopper@austcancer.com.au AUSTCANCER COMMENCES PHASE II CLINICAL STUDY OF RP101 FOR METASTATIC PANCREATIC CANCER Sydney, Australia – December 14, 2004 – Australian Cancer Technology (“AustCancer” – ASX:ACU), today said it has initiated a Phase II clinical study of RP101 for the treatment of metastatic pancreatic cancer . The eight-month study, which will include 22 patients with metastatic pancreatic cancer , will be conducted at three leading centers in Germany: Chemnitz Clinics in collaboration with the Technical University Dresden; Munich University of Technology’s Kilinikum rechts der Isar; and, University of Munich Hospital’s ...

April 6, 2005 1 DESCRIPTION This award provides $75,000 per year for three years (total $225,000) for young investigators working toward independent careers in pancreatic cancer research. OBJECTIVE The overall objective is to enable young investigators to develop independent and productive careers in pancreatic cancer research by ensuring that a major proportion of their time is protected for research. ELIGIBILITY • Candidates must hold an MD, PhD, or equivalent degree (e.g., MB, ChB, MBBS, DO). • Applicants must hold full-time faculty positions at North American universities or professional institutes at the time award begins. • Applicants must be Members of the AGA (please visit www.gastro.org for information) • The award is not intended for fellows, but for young faculty who have demonstrated unusual promise and have some record of accomplishment in research. Candidates ...

Methods The MEDLINE ® and the Cochrane Library databases were searched for articles dating from 1994 through December 2001, focusing on systematic reviews, meta-analyses, randomized controlled trials (RCTs), cost-effectiveness analyses, editorials, or commentaries concerning the critical key questions. The National Guideline Clearinghouse™ was also searched for guidelines on this topic. In the MEDLINE search, pancreatic cancer and mass screening were exploded, combining these searches with RCT terms. A second search used treatment (including chemotherapy and surgery) in place of screening. Studies of test accuracy (sensitivity and specificity) regarding screening for pancreatic cancer were also searched for. Key Questions and Results 1. Is there new direct evidence that screening provides more benefit than harm? We examined ...

Summary of Recommendation The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening for pancreatic cancer in asymptomatic adults using abdominal palpation, ultrasonography, or serologic markers. D recommendation. The USPSTF found no evidence that screening for pancreatic cancer is effective in reducing mortality. There is a potential for significant harm because of the very low prevalence of pancreatic cancer , limited accuracy of available screening tests, the invasive nature of diagnostic tests, and the poor outcomes of treatment. As a result, the USPSTF concluded that the harms of screening for pancreatic cancer exceed any potential benefits. Clinical Considerations • Because of the poor prognosis of those diagnosed with pancreatic cancer , there is an interest in primary prevention. The evidence ...

167 Burden of Suffering Cancer of the pancreas is the fifth leading cause of cancer deaths in the U.S., accounting for an estimated 27,000 deaths in 1995 (8.4 deaths/100,000 persons). 1,1a Worldwide, the age-adjusted incidence and mortality of pancreatic cancer have been increasing since the 1930s, 2,3 al- though in the U.S. these rates have declined since the early 1970s. 1,1a In- cidence rates may be overestimated, because an important proportion of pancreatic cancer diagnoses (as many as half in some studies) are not his- tologically confirmed. 4 Pancreatic cancer is more common in men, blacks, cigarette smokers, and older persons (the majority of cases being diag- nosed between ages 65 and 79). 1,2,3,5 The risk of pancreatic cancer is in- creased in patients with diabetes, including those with long-standing ...

Incidence and Mortality Rate Trends In the United States, pancreatic cancer is the fourth leading cause of cancer -related death in males and the fifth leading cause of cancer - related death in females. Because it is usually diagnosed at an advanced stage, the survival rate is poor compared to other types of cancer . Unfortunately, there has been little change in overall pancreatic cancer incidence or mortality rates throughout the past three decades. Compared to other racial and ethnic groups, African Americans are the most vulnerable to pancreatic cancer , followed by Whites. It is estimated that approximately $1.5 billion* is spent in the United States each year on treatment of pancreatic cancer . *In 2004 dollars, as reported in Brown ML, Riley GF, Schussler N, and Etzioni RD. Estimating health care costs related to cancer treatment ...

Tarceva ® (erlotinib) Tablets, NDA 21-743, S003: Supplemental NDA Briefing Document – 13 September 2005 ODAC Meeting Page 1 09 AUG 2005 Tarceva ® (erlotinib) Tablets NDA 21-743, S003 Supplemental NDA: Pancreatic Cancer Briefing Document ODAC Meeting 13 September 2005 Submission Date : 9 August 2005 58 South Service Road Melville, New York 11747 AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page 2 Tarceva ® (erlotinib) Tablets, NDA 21-743, S003: Supplemental NDA Briefing Document – 13 September 2005 ODAC Meeting Page 2 09 AUG 2005 TABLE OF CONTENTS 1 EXECUTIVE SUMMARY .. 5 2 INTRODUCTION 11 2.1 Background 11 2.2 Indication Sought and Treatment Regimen .. 11 2.3 Pancreatic Cancer and Current Treatment ...

• BASIC RESEARCH • Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice Ding-Zhong Yang, Jing He, Ji-Cheng Zhang, Zhuo-Ren Wang ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(32):4992-4996 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Ding-Zhong Yang, Department of Surgery, The First Hospital, Xi’an Jiaotong University, Xi’an 710065, Shannxi Province, China Jing He, Department of Pharmacology, University of Texas Medical Branch, Galveston 77555, Texas State, USA Ji-Cheng Zhang, Department of Surgery, Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China Zhuo-Ren Wang, Department of Surgery, The First Hospital, Xi’an Jiaotong University, Xi’an 710065, Shaanxi Province, ...

Cancer Therapy Vol 3, page 379 379 Cancer Therapy Vol 3, 379-382, 2005 Pancreatic cancer palliation using radiofrequency ablation. A new technique Case Report John D Spiliotis 1 , Anastasios C Datsis 1 , Panagiotis Chatzikostas 2 , Spyros P. Kekelos 1 , Athina N. Christopoulou 3 , Athanasios G. Rogdakis 1 , P Symeonides 2 1 Department of Surgery, “Hatzikostas” General Hospital of Messologi, Messologi, Greece 2 Department of Surgery, Nicosia General Hospital, Cyprus 3 Department of Internal Medicine, Section of Oncology, “St Andrews” General Hospital, Patras, Greece _ *Correspondence: John Spiliotis, M.D., Director of the Department of Surgery, “Hatzikostas” General Hospital of Messologi, 73 Pente ...

doi:10.1136/gut.2004.057059 2005;54;1-16 Gut Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastro-I Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Pancreatic Section of the British Society of Gastroenterology, Pancreatic Society of carcinomas pancreatic cancer periampullary and ampullary Guidelines for the management of patients with http://gut.bmjjournals.com/cgi/content/full/54/suppl_5/v1 Updated information and services can be found at: These include: Rapid responses http://gut.bmjjournals.com/cgi/eletter-submit/54/suppl_5/v1 You can respond to this article at: service Email alerting top right corner of the article Receive free email alerts when new articles cite this article - sign up in the box at the Topic collections (978 ...

Michael Rolfe Pancreatic Cancer Foundation – Betting on a Cure Reservation Form Please join us for this special fundraiser! Please complete this form and return it via mail or fax to the address/fax number below. Please submit this form prior to June 15. Note: This form is for INDIVIDUAL reservations only . If you are a Corporate Sponsor , please complete the appropriate Corporate Sponsor Form. Name of Primary Guest: This is the individual we will contact regarding logistics related to the event. Mailing address: Daytime Phone number: Primary E-mail: _ Tickets Requested Number of General Admission Tickets @ $200 per person $_ Includes Bridge* Tournaments and Casino Games. Does not include Texas Hold’em. Please check here if any of your guests are planning to play Bridge*. Number of Texas Hold’em* Tickets @ $300 per person $_ The full ticket price is tax deductible ...

• BASIC RESEARCH • Apoptosis of pancreatic cancer BXPC-3 cells induced by indole-3-acetic acid in combination with horseradish peroxidase Chen Huang, Li-Ying Liu, Tu-Sheng Song, Lei Ni, Ling Yang, Xiao-Yan Hu, Jing-Song Hu, Li-Ping Song, Yu Luo, Lu-Sheng Si ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(29):4519-4523 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Chen Huang, Li-Ying Liu, Tu-Sheng Song, Lei Ni, Ling Yang, Xiao-Yan Hu, Jing-Song Hu, Li-Ping Song, Yu Luo, Department of Cytobiology and Medical Genetics, Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China Lu-Sheng Si, College of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China Supported by the Natural ...

24 Abstract 12 Sunday 09.00 Smoking and pancreatic cancer : Animal models of pancreatic dysfunction Parimal Chowdhury There is strong evidence in the literature linking cigarette smoking with pancreatic diseases. Smoking related deaths in the United States exceed 400,000 per year. Report of the Surgeon General published in 2004 showed that an increased risk for pancreatic cancer in smokers occurs as compared to lifetime non-smokers. We believe that the development of pancreatic cancer in smokers predisposes to the induction of pancreatitis like episode and nicotine, an addictive component in the cigarette smoke, enhances this process. In an effort to understand the mechanism by which nicotine induces this process we have conducted experiments in both in-vivo animal and in in-vitro cell culture models. For in-vivo experimentation we have exposed the Male Adult Sprague Dawley rats to nicotine ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Pancreatic Cancer and Exposure to Ionizing Radiation 1 Pancreatic Cancer and Exposure to Ionizing Radiation Summary : Some evidence has been recorded of a possible connection between cancers of the pancreas and exposure to ionizing radiation. This possible connection is supported by evidence from studies conducted at Los Alamos National Laboratory and other studies of nuclear workers at other sites who have been exposed to ionizing radiation. The National Research Council’s, on the other hand, has determined that the pancreas is relatively insensitive to ionizing radiation. Pancreatic cancers are designated as “specified” cancers under the Energy Employees Occupational Illness Compensation Program Act. Historically, incidence of pancreatic cancer in ...

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE. Jay P Sharma***, Saroj K. Basak ++ ***CELPROGEN INC., SAN PEDRO, CA 90731; ++ University of California (UCLA), Los Angeles, CA. Request for off prints should be addressed to: Jay P. Sharma; email: stemcells@celprogen.com Introduction: Pancreatic cancer has markedly increased incidence over the past several decades, and ranks as the fourth leading cause of cancer death in the United States. Despite the high mortality rate associated with pancreatic cancer , its etiology is poorly understood. This discrepancy reflects the current lack of effective treatment available for the pancreatic cancer patient and highlights the urgent need for novel therapeutic approaches in this area. Celprogen’s Stem Cell based therapy for pancreatic cancer utilizes Celprogen’s ...

Capsaicin Shows Promise In Inhibiting Growth Of Pancreatic Cancer As of May 1/06 the evidence is in that capsaicin also is useful in coping with and even preventing prostae cancer . - CW ---------- Forwarded message ---------- From: Croft Woodruff < croftwoodruff@telus.net > Date: Apr 10, 2006 11:35 AM Subject: Capsaicin Shows Promise In Inhibiting Growth Of Pancreatic Cancer To: croft.woodruff@gmail.com Comment: Capsaicin stimulates digestion - particularly production of hydrochloric acid. The latter is essential to ionize minerals and hydrolyze protein fibre into chains of amino acids (peptides) that are then easily split into individual amino acids that are essential for the transport of minerals (as neutral amino acid mineral chelates) from the small intestine into the blood. Lack of HCL stimulates over production of the pancreatic enzyme trypsin to the point ...

Pancreatic Cancer 2004 Advances and Challenges June 25-26, 2004 Grand Hyatt, San Francisco, CA Annual Symposium of The Lustgarten Foundation for Pancreatic Cancer Research in collaboration with the American Association for Cancer Research and the University of California, San Francisco Conference Chairperson: Margaret A. Tempero, M.D., University of California, San Francisco, CA Abstract and Advance Registration Deadline: May 14, 2004 www.aacr.org Page 2 Annual Symposium of the Lustgarten Foundation for Pancreatic Cancer Research in collaboration with the American Association for Cancer Research and the University of California, San Francisco Conference Chairperson Margaret A. Tempero, M.D. Deputy Director, UCSF Comprehensive ...

Pancreatic Cancer at the AACR April 1-5, 2000 annual meeting Dale O’Brien, MD, MPH For educational purposes only I. Saturday Meeting-central was the Moscone Center located in the SOMA near the MOMA. That is to say, it was located in the increasingly hip section of San Francisco known as the South-of- Market area, near the Museum of Modern Art. The Moscone is an enormous block-long, half- buried against a hill, triple-decker concrete bunker kind of a building whose tall and all glass “face” fronts the whole length of the street. If it was much smaller and in Kansas, you’d call it a sod house. Today was the first day of the 91 st annual meeting of the American Association for Cancer Research—the world’s most important meeting of researchers devoted to the underlying science of cancer . The results of a meeting like this which is aimed more towards the basic ...

Pancreatic Cancer at the ASCO May 20-23, 2000 annual meeting Dale O'Brien, MD, MPH For educational purposes only It was somewhere in the French Quarter when the cab driver began his lecture regarding the location strategies of large professional meetings in the United States. "N'awlns has the third biggest convention center in the U.S.of A., just behind Vegas and Chicago. There's only a few cities that can hold a big ol' convention like this." It was true. This year's Saturday to Tuesday meeting of the American Society of Clinical Oncology ( ASCO ) had well over twenty thousand attendees from all corners of the world. And the New Orlean's Ernest N. Morial Convention Center was HUGE. It was longer than Chicago's Sears Tower (if the Tower was to unfortunately fall on its side). It was longer even than Kuala Lampur's Twin Petronas Towers in Malaysia (though some people think ...

Tumori, 90: 192-195, 2004 Correspondence to: Ozkan Kanat, MD, Uludag University Faculty of Medicine Department of Medical Oncology, Gorukle 16059, Bursa, Turkey. Tel +90-224-4428400; fax +90-224-4428049; e-mail ozkanat@uludag.edu.tr Received July 7, 2003; accepted September 8, 2003. TREATMENT OF METASTATIC PANCREATIC CANCER WITH A COMBINATION OF GEMCITABINE AND 5-FLUOROURACIL: A SINGLE CENTER PHASE II STUDY Ozkan Kanat,Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu, Murat Arslan, and Osman Manavoglu Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey Key words: chemotherapy, gemcitabine, 5-fluorouracil, pancreatic cancer . Aim : To determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer . Patients and methods : ...

Last revised: 4/21/05 UM Cancer Center Patient Education Document #0033 Apr05 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Pancreatic Cancer The purpose of this information guide is to help patients newly diagnosed with Pancreatic Cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Brochure Available free at the Patient Education Resource Center on Level B-1 room 361 National Cancer Institute. What You Need to Know ...

with medical, surgical and radiation oncologists. "The University of Chicago has expertise in every single field that deals with pancreatic cancer ," says Irving Waxman, MD, director of endoscopy at the University of Chicago and a founder of the pancreatic cancer center. From interventional endoscopy to genetics to pathology, from radiation therapy to surgery, and from standard chemotherapies to phase I, II and III trials of investigational drugs, "we have nationally known physician-scientists at every stage," Waxman said. "This is a very comprehensive program," confirms co-director Fabrizio Michelassi, MD, vice chairman of the department of surgery and section chief of general surgery. "We have strengths in all aspects of diagnosis and treatment of pancreatic cancer ." This depth, combined with the multi- disciplinary approach, is quite important," ...

#29, Inhibition of Dendritic Cell Differentiation and Activation by Pancreatic Cancer Cell Line Bxpc3: the Role of Interleukin-6 and Granulocyte Colony-Stimulating Factor Uddalak Bharadwaj, Min Li, Rongxin Zhang, Linh X. Doan, Changyi Chen, Qizhi Yao Introduction : Cancer cells have been shown to evade immune surveillance through inhibition of dendritic cell (DC) function, thereby suppressing immune responses to tumor- associated antigens. The aim of this study was to determine the effect of soluble factors released by pancreatic cancer cells on DC differentiation and activation. The change in signal transduction pathways induced by the above factors was also studied to elucidate the mechanism of immune suppression in pancreatic cancer . Methods : DCs were derived from human peripheral blood CD14 + monocytes in presence of GM-CSF plus IL-4 for 5 days (differentiation) and TNF-a for ...

A N EW M EDICINE P UBLICATION N OVEMBER 15, 2003 V OLUME 7, N UMBER 8/9 COPYRIGHT © 2003 NEW MEDICINE INC. UNAUTHORIZED PHOTOCOPYING, DISTRIBUTION OR ELECTRONIC STORAGE IS PROHIBITED BY LAW. PANCREATIC CANCER — PART I E PIDEMIOLOGY , E TIOLOGY , M OLECULAR M ARKERS , D IAGNOSIS , AND S TAGING T YPES OF P ANCREATIC C ANCER 1633 Pancreatic Intraductal/Intraepithelial Neoplasia (PanIN) 1633 Exocrine Pancreatic Cancer 1635 Pancreatic ductal adenocarcinoma (PDAC) 1635 Mucinous cystic neoplasms 1635 Intraductal papillary mucinous tumors (IPMT) ...

Reference Section a report by Gauri R Varadhachar y , MD and James L Abbr uzzese , MD , FACP Assistant Professor, and Chairman, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center Introduction Pancreatic cancer is the fourth leading cause of cancer - related death and has the highest case fatality rate. In 2004, approximately 31,860 new cases will be diagnosed, and 31,270 of affected patients are expected to die from their disease. 1 Patients usually present with advanced disease, and two-thirds of them either have locally advanced or metastatic disease. Presentation may depend on location of the primary, with more pain in patients with tumors involving the body and tail of the pancreas,and obstructive jaundice in patients ...

research for a cure laboratory without walls National Foundation for Cancer Research Cancer FAQs about Pancreatic cancer Frequently Asked Questions about common cancers. Page 2 About Pancreatic Cancer The pancreas is located behind the stomach, extending horizontally across the middle of the abdomen. Its shape is often described as a long fish, because it is wide at one end (commonly referred to as the “head” of the pancreas) and narrow at the other (the “tail”). Overall, it is about six inches long and two inches wide. The pancreas is very complex, functioning as two separate glands ( exocrine and endocrine ) inside the same organ.The vast majority of pancreatic cells function as exocrine glands and ducts.The exocrine glands make pancreatic juice, which contains enzymes that break down fats, proteins and carbohydrates ...